文献速递心律失常

DOACs对比华法林在亚洲与非亚洲房颤患者中的疗效与安全性:COMBINE AF个体患者荟萃分析

Direct oral anticoagulants vs warfarin in Asian vs non-Asian patients with atrial fibrillation: a patient-level meta-analysis from COMBINE AF.
PubMed 文献 · Eur Heart J · 2026-01-01

亚洲患者较非亚洲患者体重更轻、肾功能更差、卒中史比例更高,且华法林治疗窗内时间更低。与华法林相比,标准剂量DOACs在亚洲患者中对卒中/体循环栓塞、大出血和主要净临床结局的降低幅度均显著优于非亚洲患者,且未增加消化道出血风险。

要点

  • 亚洲房颤患者使用标准剂量DOACs较华法林的获益幅度大于非亚洲患者,尤其在卒中/栓塞和大出血的减少上。
  • 标准剂量DOACs在亚洲患者中未增加消化道出血风险,优于华法林和低剂量DOACs。
  • 标准剂量DOACs在亚洲患者中应优先于华法林或低剂量DOACs使用。

核心结论

  • 与华法林相比,标准剂量DOACs在亚洲房颤患者中的临床净获益比在非亚洲患者中更显著。
  • 在亚洲患者中,标准剂量DOACs未增加消化道出血风险,相较于华法林或低剂量DOACs应作为优选。

研究设计与样本

  • 基于COMBINE AF合作的四项比较DOACs与华法林在房颤患者中疗效的随机试验的个体患者水平荟萃分析。

主要发现

  • 在亚洲患者中,标准剂量DOACs在较宽的体重和肌酐清除率范围内均可降低临床事件风险;与标准剂量相比,低剂量DOACs显著增加卒中/栓塞风险(HR 1.57, 95%CI 1.15-2.13)。

临床怎么用

  • 对亚洲房颤患者,标准剂量DOACs应作为优先于华法林及低剂量DOACs的抗凝选择,尤其在出血风险担忧时更应避免不恰当地减低剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Large-scale randomized data comparing clinical outcomes of atrial fibrillation patients of Asian vs non-Asian races are limited. METHODS: Data from A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation, which pooled patient-level data from the four pivotal randomized trials of direct oral anticoagulants (DOACs) vs warfarin in patients with atrial fibrillation, were analysed. Baseline characteristics and clinical outcomes in patients of Asian race (Asians) vs non-Asian race were compared. The relative efficacy and safety of DOACs compared with warfarin in Asians vs non-Asians, assessing for interactions between race and treatment effect, were investigated. Outcomes across the range of body weight and creatinine clearance in Asians were also explored. RESULTS: A total of 10 212 Asian patients and 61 471 non-Asians were identified. Compared with non-Asians, Asians were on average 3.2 years younger and 20 kg lighter, had worse renal function (mean creatinine clearance 64.9 vs 77.3 mL/min), and had higher rates of prior stroke/transient ischaemic attack (37.2% vs 26.6%) (P < .001 for each). In the warfarin arm (median time in therapeutic range 57.7% for Asians vs 66.2% for non-Asians, P < .001), Asians had a higher adjusted risk of stroke/systemic embolic events (SEEs), major bleeding, intracranial haemorrhage, gastrointestinal bleeding, and primary net clinical outcome (stroke/SEE, major bleeding, or death). Compared with warfarin, standard-dose (SD) DOACs significantly reduced the risks in Asians to a greater degree than non-Asians for stroke/SEE (hazard ratio [HR] .65, 95% confidence interval .53-.80 vs HR .86, 95% confidence interval .78-.95), major bleeding (HR .62 [.52-.75] vs HR .91 [.84-.98]), and primary net clinical outcome (HR .76 [.68-.85] vs HR .94 [.90-.98]; Pint < .02 for each). Standard-dose DOACs increased gastrointestinal bleeding only in non-Asians (Asians HR .92 [.69-1.23] vs non-Asians HR 1.41 [1.25-1.58], Pint = .009). In Asians, SD DOACs reduced the risks of clinical events across the wide range of body weight and creatinine clearance. Compared with SD DOACs, lower-dose DOACs significantly increased the risk of stroke/SEE (HR 1.57 [1.15-2.13]) and secondary net clinical outcome (stroke/SEE, intracranial haemorrhage, or death; HR 1.23 [1.03-1.48]) in Asians. CONCLUSIONS: Clinical outcomes with SD DOACs vs warfarin in patients with atrial fibrillation were generally even more favourable in patients of Asian than non-Asian race. Compared with warfarin, SD DOACs did not increase the risk of gastrointestinal bleeding in Asians. Standard-dose DOACs are preferred over warfarin or lower-dose DOACs in patients of Asian race.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Chao, Braunwald, Palazzolo, et al. Direct oral anticoagulants vs warfarin in Asian vs non-Asian patients with atrial fibrillation: a patient-level meta-analysis from COMBINE AF. Eur Heart J. 2026. PMID: 42059513. doi:10.1093/eurheartj/ehag246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。